Abstract
Fourteen patients with cisplatin-refractory germ cell tumors (GCT) were treated with temozolomide on a phase II trial. Temozolomide was given orally at 150 mg/m2/day on days 1-5. The cycle length was 28 days. No patient experienced a grade 3 or 4 toxicity, and none of the 14 evaluable patients achieved a complete or partial response. Temozolomide is not efficacious in the treatment of cisplatin-refractory GCT patients.
Original language | English |
---|---|
Pages (from-to) | 177-179 |
Number of pages | 3 |
Journal | Investigational New Drugs |
Volume | 22 |
Issue number | 2 |
DOIs | |
State | Published - Apr 2004 |
Externally published | Yes |
Keywords
- Cisplatin-refractory
- Germ cell tumor
- Nonseminoma
- Phase II
- Temozolomide